HDAC inhibitors (HDACi) can activate tumor suppressor genes and promote tumor cell killing, which have been evaluated in clinical trials for adult AML patients with limited efficacy, either alone or in combination with chemotherapy (97). The gene discussed is HDAC9; the disease is acute myeloid leukemia.